PMID- 32866960
OWN - NLM
STAT- MEDLINE
DCOM- 20211013
LR  - 20211013
IS  - 2235-3186 (Electronic)
IS  - 1660-8151 (Linking)
VI  - 144
IP  - 11
DP  - 2020
TI  - Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal 
      Anemia: A Meta-Analysis of Randomized Trials.
PG  - 572-582
LID - 10.1159/000508812 [doi]
AB  - BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are 
      a new class of treatment for renal anemia in patients with chronic kidney disease 
      (CKD). This meta-analysis was designed to evaluate their efficacy and safety. 
      METHOD: Eight databases were searched for randomized controlled trials (RCTs). 
      Information about efficacy and safety was extracted and combined using 
      random-effects or fixed-effects models, depending on heterogeneity. Risk of bias 
      was assessed using the method recommended by the Cochrane Centre. RESULTS: 
      Nineteen articles on RCTs were selected, involving 3,289 participants. We found 
      that HIF-PHIs improved the level of hemoglobin (Hb) (weighted mean difference 
      [WMD] 1.40; 95% CI: 0.96-1.84; p < 0.001), response rate of Hb (risk ratio [RR] 
      5.95; 95% CI: 3.95-8.96; p < 0.001), and total iron-binding capacity (WMD 42.94; 
      95% CI: 31.39-54.49; p < 0.001), while reducing the level of hepcidin (WMD 
      -40.42; 95% CI: -50.44 to -30.39; p < 0.001), ferritin (WMD -64.60; 95% CI: 
      -78.56 to -50.64; p < 0.001), and transferrin saturation (WMD -5.57; 95% CI: 
      -8.53 to -2.61; p < 0.001). Meanwhile, there was no evidence of effect on serum 
      iron (WMD 1.60; 95% CI: -3.72 to 6.93; p = 0.55), nor on the incidence of adverse 
      events (AEs) (RR 1.06; 95% CI: 0.99-1.15; p = 0.51) or of serious adverse events 
      (SAEs) (RR 1.14; 95% CI: 0.88-1.46; p = 0.32). CONCLUSION: HIF-PHIs ameliorate 
      renal anemia and rectify iron metabolism in the short term without increasing the 
      incidence of AEs and SAEs.
CI  - (c) 2020 S. Karger AG, Basel.
FAU - Wen, Tong
AU  - Wen T
AD  - Department of Nephrology, Shenzhen People's Hospital, The Second Affiliated 
      Hospital, Jinan University, Shenzhen, China.
FAU - Zhang, Xinzhou
AU  - Zhang X
AD  - Department of Nephrology, Shenzhen People's Hospital, The Second Affiliated 
      Hospital, Jinan University, Shenzhen, China, xin.zhou2@qq.com.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Department of Nephrology, Shenzhen People's Hospital, The Second Affiliated 
      Hospital, Jinan University, Shenzhen, China.
FAU - Zhou, Ru
AU  - Zhou R
AD  - Department of Nephrology, Shenzhen People's Hospital, The Second Affiliated 
      Hospital, Jinan University, Shenzhen, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200831
PL  - Switzerland
TA  - Nephron
JT  - Nephron
JID - 0331777
RN  - 0 (Hemoglobins)
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Prolyl-Hydroxylase Inhibitors)
SB  - IM
MH  - Anemia/complications/*drug therapy/metabolism
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/*metabolism
MH  - Prolyl-Hydroxylase Inhibitors/*therapeutic use
MH  - *Randomized Controlled Trials as Topic
MH  - Renal Insufficiency, Chronic/complications/*drug therapy/metabolism
OTO - NOTNLM
OT  - Hypoxia-inducible factor prolyl hydroxylase inhibitors
OT  - Meta-analysis
OT  - Renal anemia
EDAT- 2020/09/01 06:00
MHDA- 2021/10/14 06:00
CRDT- 2020/09/01 06:00
PHST- 2019/11/18 00:00 [received]
PHST- 2020/05/17 00:00 [accepted]
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2021/10/14 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - 000508812 [pii]
AID - 10.1159/000508812 [doi]
PST - ppublish
SO  - Nephron. 2020;144(11):572-582. doi: 10.1159/000508812. Epub 2020 Aug 31.